Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy
Topic overview
This study demonstrates that oral EPA supplementation (20-40 mg/kg/day) significantly reduces liver fibrosis progression in biliary atresia patients who achieved jaundice clearance after laparoscopic Kasai portoenterostomy. While EPA did not improve initial jaundice clearance rates, treated patients showed lower fibrosis markers and improved APRI scores at 2 years post-surgery.
Key takeaways
- EPA administration (20-40 mg/kg/day) reduced liver fibrosis progression in BA patients after Kasai portoenterostomy who achieved jaundice clearance.
- EPA-treated patients showed significantly lower M2BPGi levels and improved APRI scores at 2 years post-surgery compared to untreated controls.
- EPA did not improve clearance of jaundice rates but provided hepatoprotective benefits in the post-operative period for jaundice-free patients.
- Liver fibrosis remains a challenge in BA even after successful jaundice clearance, warranting adjunctive medical therapies like EPA.
- Laparoscopic Kasai portoenterostomy combined with EPA may offer a dual approach to managing BA: surgical drainage plus anti-fibrotic therapy.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy. GlobalCastMD Medical Library. 2024-08-21. https://dev.library.globalcastmd.com/article/9049?via_space=staycurrentmd
Comments